> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Ocugen Reports Positive Phase 2 Data for Vision Loss Gene Therapy
- URL: https://www.fdaweb.com/ocugen-reports-positive-phase-2-data-for-vision-loss-gene-therapy/
- Published: 2026-03-24T12:00:00.000Z
- Updated: 2026-09-14T13:36:02.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5160869

Ocugen is announcing encouraging 12-month results from a mid-stage clinical trial of its experimental gene therapy OCU410, aimed at treating geographic atrophy, an advanced form of dry age-related macular degeneration that leads to irreversible vision loss.

According to the company, patients receiving the optimal dose of OCU410 in the Phase 2 ArMaDa trial experienced a 31% reduction in lesion growth compared to untreated controls, meeting statistical significance. The therapy also demonstrated signs of preserving retinal structure, with a 27% slower rate of photoreceptor degeneration, it says.

Ocugen says the results compare favorably to currently approved therapies, which have shown lesion growth reductions of approximately 15% at one year and 22% at two years. If confirmed in later-stage trials, OCU410 could represent a more effective option in a market where treatment choices remain limited.

Unlike existing drugs that require frequent injections — often six to twelve per year — OCU410 is being developed as a one-time gene therapy, potentially reducing the treatment burden that contributes to patient dropout in real-world settings.

The company notes that no serious adverse events linked to the therapy to date, and no cases of significant eye-related complications such as retinal detachment or inflammation.

Company executives say the results support advancing OCU410 into a Phase 3 registrational trial, expected to begin in the third quarter. The planned study could enroll up to 300 patients and will use an adaptive design to confirm efficacy and safety.